Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
– Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease
- A Review of Cost-effectiveness Analyses for Anemia in Chronic Kidney Disease; Poster #188;
- Descriptions of Anemia Symptoms: A Linguistic Analysis of Social Media Conversations in Chronic Kidney Disease; Poster #190;
- Targeted Review of the Epidemiology and Burden of Anemia in Chronic Kidney Disease; Poster #191; and
- Targeted Literature Review of the Patient-reported Burden of Anemia in Chronic Kidney Disease; Poster #192.
"Akebia and Otsuka are committed to innovation and quality clinical research to advance the standard of care for patients with kidney disease," said
Presenters will be available for questions at posters on
About Akebia Therapeutics
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include
OPDC is an indirect subsidiary of
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.
This document contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “create,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “position,” “predict,” “potential,” “opportunity,” “working to,” “look forward” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding advancing the standard of care for patients with kidney disease, and increasing awareness and understanding of the economic burden and challenges faced by patients with anemia due to chronic kidney disease, are forward-looking statements. Important factors could cause actual results to differ materially from Akebia’s plans, estimates or expectations. Other risks and uncertainties include those identified under the heading “Risk Factors” in Akebia’s Annual Report on Form 10-K, and other filings that Akebia may make with the
Kristen K. Sheppard, Esq.
Otsuka In U.S.
Otsuka America Pharmaceutical, Inc.
Otsuka Outside U.S.
Leader, Pharmaceutical PR
Otsuka Pharmaceutical, Co., Ltd.
+81 3 6361 7379, +81 80 8728 6039